Sit Less and Move More: Feasibility Study

Sedentary Behavior Clinical Trial

Official title:

Sit Less and Move More: A Feasibility Study on Physical Active Break Intervention and Improving Cardiometabolic Health

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06427603
• Other study ID #: RD/2022/2.12
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 2024
• Est. completion date: January 2025

Study information

• Verified date: May 2024
• Source: Hong Kong Metropolitan University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Intervention aiming to improve cardiometabolic health by reducing prolonged sitting

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: January 2025
• Est. primary completion date: October 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

1. are community-dwelling older adults aged 65 years or above,

2. are smartphone users,

3. sit for >= 6 hours per day

4. are overweight

Exclusion Criteria:

1. are unable to walk independently with/without walking aids due to a physical disability;

2. have health conditions that hinder the adherence to intervention

Related Conditions & MeSH terms

• Sedentary Behavior

Intervention

Behavioral:
• physical activity
workshops and mobile apps: break sedentary behavior by activity breaks

Locations

Country	Name	City	State
Hong Kong	School of Nursing and Health Studies, Hong Kong Metropolitan University	Ho Man Tin

Sponsors (1)

Lead Sponsor	Collaborator
Hong Kong Metropolitan University

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intervention feasibility	will be assessed using a scale "Feasibility, appropriateness, and acceptability of the intervention"	T2: post-intervention (week 12)
Secondary	Sedentary behavior	will be assessed using an accelerometer	T1: baseline (before the study begins)
Secondary	Sedentary behavior	will be assessed using an accelerometer	T2: post-intervention (week 12)
Secondary	Sarcopenia score ranged from 0 to 20	will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)	T1: baseline (before the study begins)
Secondary	Sarcopenia score ranged from 0 to 20	will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)	T2: post-intervention (week 12)
Secondary	Blood glucose	will be assessed using a portable blood monitoring device	T1: baseline (before the study begins)
Secondary	Blood glucose	will be assessed using a portable blood monitoring device	T2: post-intervention (week 12)
Secondary	Blood lipid	will be assessed using a portable blood monitoring device	T1: baseline (before the study begins)
Secondary	Blood lipid	will be assessed using a portable blood monitoring device	T2: post-intervention (week 12)
Secondary	Blood pressure	will be assessed using a portable blood monitoring device	T1: baseline (before the study begins)
Secondary	Blood pressure	will be assessed using a portable blood monitoring device	T2: post-intervention (week 12)
Secondary	Muscle strength (handgrip strength)	will be assessed using a hand-held dynamometer	T1: baseline (before the study begins)
Secondary	Muscle strength (handgrip strength)	will be assessed using a hand-held dynamometer	T2: post-intervention (week 12)
Secondary	Physical performance	will be assessed using Time-Up-to-Go (TUG)	T1: baseline (before the study begins)
Secondary	Physical performance	will be assessed using Time-Up-to-Go (TUG)	T2: post-intervention (week 12)